Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab plus concurrent chemoradiotherapy vs placebo for locally advanced cervical cancer
ChiCTR2600125844Phase 3Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Jun 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of adebrelimab in Cervical Cancer (CC) (4 arms), sponsored by Fudan University Shanghai Cancer Center. Primary endpoints: Progression-free survival and Overall survival. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2600125844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125844.